The Pharma Data

AUGUST 3, 2021

The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads. The research team, including scientists from the U.S.

Virus 52

Virus Clinical Trials Drugs Laboratories 52

Broad Institute

APRIL 25, 2024

He started to imagine how the deadly and contagious disease, if confirmed, might spread to half the city’s population. Eight of the 20 patients died, but the spread of the disease in Nigeria stopped there. Blood and urine samples from the man were waiting for Happi in his lab. Happi felt chilled. They called the idea Sentinel.

Virus 132

Virus Hospitals Disease Government 132

PLOS: DNA Science

MAY 16, 2024

These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. COVID clearly caught us off guard.

Virus 98

Virus DNA RNA Laboratories 98

The Pharma Data

SEPTEMBER 4, 2020

The main test used to diagnose coronavirus is so sensitive it could be picking up fragments of dead virus from old infections, scientists say. He believes the detection of traces of old virus could partly explain why the number of cases is rising while hospital admissions remain stable. Image copyright. Getty Images.

Virus 52

Virus Hospitals Disease Research 52

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. Singapore biotechnology company. population.

Virus 52

Virus Immune Response Vaccine Research 52

The Pharma Data

DECEMBER 29, 2020

Experts believe brain-related effects may be tied to the body’s immune response to the virus and possibly to vascular problems or surges of inflammation caused by the disease. WHO is working with scientists around the world to “better understand any and all changes to the virus” and their impact, he said.

Virus 52

Virus Hospitals Immune Response Doctors 52

The Pharma Data

DECEMBER 21, 2020

The team at the Walter Reed Army Institute of Research is checking genetic sequences of the mutated virus variant posted online by British researchers, CNN reported. Centers for Disease Control and Prevention. © 2020 HealthDay. Posted: December 2020. The CDC said more than 190.4 million doses to 45.3 million as of Nov.

Packaging 52

Packaging Vaccine Laboratories Virus 52

The Pharma Data

NOVEMBER 18, 2020

Antimicrobial resistance occurs when microorganisms resist the effects of medications, making infections harder to treat and increasing the risk of disease spread, severe illness and death. HIV drug resistance is caused by changes in the genetic structure of HIV that affects the ability of drugs to block the replication of the virus.

Laboratories 52

Laboratories Therapies Virus Government 52

The Pharma Data

NOVEMBER 17, 2020

17, 2020 — From 2009 to 2018, there were increases in diseases-of-despair diagnoses, according to a study published online Nov. Diagnoses related to alcohol misuse, substance misuse, and suicide ideation/behaviors were defined as diseases of despair. © 2020 HealthDay. Posted: November 2020. TUESDAY, Nov.

Disease 52

Disease Virus Research Drugs 52

Codon

AUGUST 26, 2024

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus.

RNA 84

RNA Virus DNA Vaccine 84

The Pharma Data

MARCH 3, 2022

Today’s decision is a pivotal next step in our path towards potential regulatory approval for our maternal RSV vaccine candidate and is an important milestone in our efforts to help address the detrimental impact RSV disease has on infants,” said Kathrin U. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

DECEMBER 31, 2020

Monthly News Roundup – December 2020. In studies, the vaccines were found to be 94% to 95% effective in preventing COVID-19 disease. The messenger RNA (mRNA) vaccines encode a form of the spike (S) protein of SARS-CoV-2 virus. The partial piece of the spike protein cannot cause COVID-19 disease.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

The Pharma Data

DECEMBER 30, 2020

The year 2020 will certainly go down in history as the year of COVID-19. Gilead Sciences Makes Multiple Bets : When Gilead Sciences wasn’t working on remdesivir in COVID-19, the company seemed to be constantly flexing its M&A muscle over the course of 2020. It began in May with the $4.9

Science 52

Science Disease Pharmaceuticals Treatment 52

The Premier Consulting Blog

JUNE 18, 2023

One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases. However, with rare diseases there may be no available treatments that could serve as SoC or active control in a clinical trial and assigning patients to placebo may be unethical.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

Drug Target Review

AUGUST 11, 2023

In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. Since December 2019, SARS-CoV-2 (COVID-19) infection has become a worldwide urgent public health concern.

Vaccine 98

Vaccine Immune Response Bioinformatics Virus 98

The Pharma Data

NOVEMBER 3, 2020

Centers for Disease Control and Prevention study collected data on more than 400,000 symptomatic women aged 15 to 44, of whom more than 23,000 were pregnant. ” Prime Minister Boris Johnson also had the virus in the spring. © 2020 HealthDay. Posted: November 2020. He was admitted to the hospital, but recovered.

Hospitals 52

Hospitals Laboratories Doctors Virus 52

The Pharma Data

MAY 15, 2023

CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV) Gilead Sciences, Inc. Bulevirtide was initially granted conditional marketing authorisation in July 2020 to provide people living with HDV urgent access to treatment. In the U.S.

Virus 40

Virus Marketing Treatment Science 40

The Pharma Data

APRIL 14, 2021

The product’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most virulent Marek’s disease virus strains. Its purpose is to provide poultry producers with cutting-edge technology in terms of Marek’s disease protection.

Vaccine 52

Vaccine Disease Virus Engineering 52

The Pharma Data

DECEMBER 2, 2020

3, 2020 09:00 UTC. MTX-COVAB was also found to have virus neutralizing potency (IC50= 40pM), which is comparable or better to that of the leading antibody therapies in development, and cross-neutralizes all clinically relevant virus mutants. Memo Therapeutics AG is a private company located in Bio-Technopark Zurich, Switzerland.

Disease 52

Disease Virus Treatment Therapies 52

The Pharma Data

DECEMBER 5, 2020

5, 2020 — A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Lewis Hsu, chief medical officer of the Sickle Cell Disease Association of America. SATURDAY, Dec.

Therapies 52

Therapies Disease Medical Schools Virus 52

New Drug Approvals

DECEMBER 26, 2022

1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4*01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03 Immunoglobulin g1, anti-(human respiratory syncytial virus fusion protein)(human monoclonal med18897.gamma.1-chain), 2020) Dosage regimens for and compositions including anti-rsv antibodies. 2020/0347120 A1).

Virus 52

Virus Clinical Trials Trials Disease 52

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. It has been well established that exposure to wild-type AAV results in priming of the immune system against the virus. Nature 578 , 229-236 (2020). References Doudna JA. Ylä-Herttuala S.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

OCTOBER 29, 2020

29, 2020– Alexion Pharmaceuticals, Inc. NASDAQ:ALXN) today announced financial results for the third quarter of 2020. Non-GAAP diluted EPS for the third quarter of 2020 was $3.24 , a 16 percent increase versus the third quarter of 2019. ” Third Quarter 2020 Financial Highlights. in the prior year.

Clinical Trials 40

Clinical Trials Trials Production Licensing 40

The Pharma Data

NOVEMBER 5, 2020

5, 2020 /PRNewswire/ — Third quarter 2020 revenues increased 32% to $2.29 Third quarter 2020 EYLEA ® U.S. Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07

Production 52

Production FDA Trials FDA Approval 52

The Pharma Data

DECEMBER 10, 2020

The FDA said Thursday that it has developed a test for COVID-19 in fecal matter, in an attempt to prevent the disease from being inadvertently transmitted during fecal transplantation. We know now that the viral RNA is found in stool and infectious virus as well. 1, 2019, until effective screening methods are implemented.”.

FDA 52

FDA Laboratories RNA Virus 52

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. Valneva and Pfizer entered into a collaboration agreement in April 2020 to co-develop VLA15 2. About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

The Pharma Data

DECEMBER 9, 2020

10, 2020 04:32 UTC. The offering is expected to close on or about December 14, 2020, subject to satisfaction of customary closing conditions. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases.

Pharmaceuticals 40

Pharmaceuticals Clinical Trials Therapies Trials 40

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.

Disease 52

Disease FDA Treatment Clinical Trials 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

With support from a 2020 NIH Director’s Pioneer Award, Veesler will study members of the order Chiroptera. These days, the Veesler lab has been hard at work to understand SARS-CoV-2 and the human immune response to the virus. 2020 Apr 16;181(2):281-292.e6. Or, more colloquially, bats. Veesler says bats are remarkable creatures.

Virus 52

Virus Immune Response Clinical Trials Treatment 52

The Pharma Data

OCTOBER 31, 2020

Since the first cases were reported in March 2020 , there have been 234,511 cases of COVID-19, including 10,136 deaths reported in Canada ; these cumulative numbers tell us about the overall burden of COVID-19 illness to date. OTTAWA, ON , Nov. The number of people experiencing severe illness continues to increase.

Assisted Living 40

Assisted Living Hospitals Disease Laboratories 40

The Pharma Data

NOVEMBER 6, 2020

6, 2020 — As the daily U.S. universities reopened their campuses to students in some capacity this fall, the newspaper said, and some schools have appeared to keep the virus in check, primarily through extensive testing programs. © 2020 HealthDay. Posted: November 2020. FRIDAY, Nov. More than a third of U.S.

Virus 40

Virus Vaccine Government Doctors 40

The Pharma Data

DECEMBER 22, 2020

22, 2020 — A new study may prove reassuring for expectant moms: Pregnant women who are infected with COVID-19 during their third trimester appear unlikely to pass the infection to their fetuses. Researchers evaluated the levels of virus in respiratory, blood and placental tissue samples. TUESDAY, Dec.

Virus 52

Virus Vaccine Disease Hospitals 52

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. Autoimmune disease impacts different parts of the body, weakening functionality. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. It may be life-threatening.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

Broad Institute

JANUARY 30, 2024

Bhattacharyya wears many coats today, splitting his time between the Broad and the infectious disease ward at MGH, where a diagnostic method he developed at Broad is now being tested to see if it helps patients quickly receive the best antibiotics for their infections.

Hospitals 137

Hospitals Medical Schools Virus Science 137

PLOS: DNA Science

JUNE 13, 2024

The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. An altered virus could have escaped. Evidence that the virus emerged, or escaped, from the wildlife trade is lacking. Her points: 1. Coincidence? I’ve never thought so.

Virus 52

Virus RNA DNA Science 52

Codon

AUGUST 27, 2024

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.

DNA 81

DNA Laboratories Hospitals Virus 81

EG Life Sciences

FEBRUARY 15, 2023

To perform this, CDER is required to understand the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat. Approval processes were slow in comparison to 2020 and 2021, where 53 and 50 approvals were achieved respectively.

Drug Development 52

Drug Development FDA Approval Drugs Virus 52